Alfredo Addeo MD

What happens to pts with resectable NSCLC who don’t make it to surgery after neoadjuvant chemo-immunotherapy?@JTOonline In this multicenter study (n=57), definitive RT is a valid alternative: 👉 1-year OS 81% 👉 mPFS 16.1 mo 👉 Pneumonitis 18% 🔬 pubmed.ncbi.nlm.nih.gov/41852936/

Great discussion today at the Virtual Healthbook CME Webinar on NSCLC EGFR+ Honored to chair and speak alongside dr Girard and dr Dummer. Key takeaway: translating molecular insights into RW treatmen remains both our biggest challenge and opportunity. @EGFRResister

More disappointment with anti-TIGIT therapy. Results from phase III KEYVIBE-010 study of adjuvant vibostolimab coformulated with pembrolizumab versus pembro alone in resected melanoma fails to improve recurrence free survival (HR 1.25) and adds toxicity. thelancet.com/journals/lanon…

@mihaela_aldea @DanaFarber @GustaveRoussy @AlkRos1France Couldn’t agree more.. and congrats for the article

With multiple MTA-cooperative #PRMT5i now in phase 1/2 trials, MTAP testing should be considered in oncogene-driven #NSCLC. More than 1 in 3 patients with ALK+ disease may harbor MTAP loss. Next step: TKI + PRMT5i combination trials. @DanaFarber @GustaveRoussy @AlkRos1France @ALKPositiveinc

Is there any better way to start the day than dissecting such a controversial trail at our journal club ? @apmariniello @PTarantinoMD @Timothee_MD

Great discussions today in Florence 🇮🇹 at "Thoracic Oncology: Current and Upcoming Treatment Strategies." Insightful lectures from @BenjaminBesseMD , sharing a forward-looking vision for lung cancer treatment, and @Alfdoc2, highlighting key areas where ADCs still need improvement.

@StephenVLiu @benlevylungdoc @PatelOncology What a great trio

Ready for some spirted discussion on the current best approaches to treating lung cancer at the “Summit at the Summit” in Utah with @benlevylungdoc and @PatelOncology.

@ACortelliniMD talking about 2nd line therapy:do we have enough evidence?

@ScaltritiLab @camuso_angela @RoVannacci A me colpisce come nessuno parli di 1)età dei genitori che è aumentata (datore di rischio) 2) miglioramento delle tecniche di neo- rianimazione per i bambini prematuri (prematuri hanno rischio elevato)… insomma mi pare una bella strumentalizzazione come sempre

@camuso_angela @RoVannacci Dal 1982 le gastriti da Helicobacter pylori sono aumentate del 10000000%. Indovini perché?

“In Italia autismo in 45 anni aumentato del ventimila per cento,quali correlazioni con i vaccini” Cristina Costa contro obbligo vaccinale a neonati mostra a ⁦@RoVannacci⁩ alcuni dati. Il convegno sabato a Roma, dove Angela Camuso ha radunato l’Avanguardia del dissenso

Prof Besse lecturing us on current advantages and future perspectives in NSCLC-what’s next.

Prof Annunziato on why do we need to know to understand immunotherapy for lung cancer .

Dr Toschi on the unresecable Stage III NSCLC present and future challenges

Dr Cappuzzo now on resecting oncogene addicted NSCLC.

Dr Voltolini now giving a clear view on role of surgery. Challenging to define consensual definition of resectable.

@MARIANOPROVENCI giving his take on a very hot topic new treatment paradigms in resectable NSCLC.

@PassigliaFra has just kicked off the III edition of the “thoracic oncology:current and upcoming treatment strategies” in Florence. Great summary on lung cancer screening.

Results from ELIOS @CD_AACR: patients with EGFR mutant NSCLC had paired pre/post biopsies for NGS. At progression, most common acquired alterations were MET amp (17%), CDKN2A/B del (15%), MTAP (13%), C797S (13%). TROP2 expression independently high. aacrjournals.org/cancerdiscover…

T cell engagers are transforming small cell lung cancer but why is NSCLC lagging behind? During our Year in Review roundtable @MartinReck2 and @peters_solange debated the future of this technology with @charlesrudin. They explored whether the unique immune environment of SCLC is the key to their success and what this means for other immunotherapy strategies moving forward. Watch the roundtable here ⬇️ lungsummit.org/all-sessions/

@CruzAPhD @CCR_AACR @MARIANOPROVENCI @gecp_org @sierra_belen @angelesgilg you guys are just an incredible collaborative group. Congrats

🎉Our latest research published in @CCR_AACR. doi.org/10.1158/1078-0… We provide the most comprehensive multiomic🧬 characterization to date of the B-cell 🫧 mediated immune response in resectable NSCLC 🫁 treated with perioperative chemoimmunotherapy (ChIO). @MARIANOPROVENCI

March is #MarsBleu, the month dedicated to raising awareness about colorectal cancer screening. Today at HUG Geneva , we discussed the importance of organized screening programs to detect cancer earlier and save lives.